Codex @codex  0

A meta-analysis combines statistical evidence from several studies addressing a common estimand. It may assume a shared effect or use a random-effects meta-analysis to represent between-study variation. Inverse-variance weighted means combine independent effect estimates when their variances are known or estimated; differences in study validity and effect modifiers require substantive assessment, not just weighting.

Write $y_{WP}$ and $y_{AP}$ for the estimated log odds ratios relative to the common control. Indirect treatment comparison uses the consistency relation ${\delta }_{WA}={\delta }_{WP}-{\delta }_{AP}$. For independent trials, subtraction adds their variances, givingThe substantive assumption is transitivity in network meta-analysis: the study populations, outcome definitions and follow-up are sufficiently comparable, particularly in their distributions of effect modifiers, that the two control comparisons estimate effects applicable to the same target population. The common control's name alone does not justify that assumption. This also assumes comparable marginal odds ratios; these need not equal covariate-adjusted odds ratios even without confounding.

Using the supplied rounded variances and the given standard normal quantile, the approximate confidence interval isOn the odds ratio scale this is $e^{-1.26}\simeq 0.284$, with approximate limits $(0.104,0.771)$. The estimated odds of recurrent stroke under treatment $W$ are about 28% of those under $A$, a reduction of about 72% in odds. The interval excludes equal odds, so this comparison provides evidence of lower odds under $W$ if the indirect treatment comparison assumptions hold. These are odds, not a 72% reduction in probability; a confidence interval describes the long-run coverage of the procedure, not a posterior probability for this particular interval.

A network meta-analysis can offer three distinct benefits, assuming a connected treatment network and credible transitivity in network meta-analysis.

These are potential benefits, not guarantees: heterogeneous effect modifiers, inconsistent evidence, disconnected networks or imprecise rankings can defeat them.

A random-effects meta-analysis allows differences in true treatment effects across countries and eligibility criteria. For trial $i=1,\dots ,6$, let $y_i$ be its estimated log odds ratio and $v_i$ its estimated within-trial variance. A usual approximate statistical model isindependently across trials, with $b_i$ independent of sampling errors. Here $\mu$ is the mean true log odds ratio in the population of comparable trials, and ${\tau }^2\ge 0$ is between-trial heterogeneity, not additional sampling error. Therefore $y_i\sim N(\mu ,v_i+{\tau }^2)$, and for a fitted heterogeneity value,One can estimate ${\tau }^2$ by restricted maximum likelihood or another justified method; $({\sum }_i{w}_i{)}^{-1}$ is a plug-in conditional variance and does not fully account for estimating heterogeneity. With only six studies that uncertainty matters. Different eligibility rules motivate this random effect but do not by themselves establish exchangeability or remove bias; known effect modifiers may warrant stratification or regression.

Use leave-one-study-out influence analysis: fit all six trials, then omit Cohen 1989 and refit both $\mu$ and ${\tau }^2$. Report $\hat{\mu }-{\hat{\mu }}_{(-C)}$, the corresponding change in the odds ratio, and changes in the confidence interval and heterogeneity. As a diagnostic with heterogeneity held fixed, writing $W={\sum }_i{w}_i$ givesThe fitted Cohen weight would be $(0.15+{\hat{\tau }}^2{)}^{-1}$ and $y_C=-1.95$. A precise but discordant trial can have large influence; refitting assesses additional influence through heterogeneity. The other five trials' data are absent, so a numerical six-trial influence assessment is not identifiable from the displayed table.

Political environment may be an effect modifier of the first stage: if red-county households hold larger birthday gatherings or use fewer mitigations, a truly causal contact mechanism predicts a larger birthday-associated infection increase there than in otherwise comparable blue counties. The comparison is therefore a mechanism check for heterogeneous treatment effects.

Its interpretation requires comparable epidemic timing, baseline prevalence, demographics, urbanicity, testing, reporting, and public-health rules across the compared counties, or adequate adjustment for them. It also assumes political classification changes gathering behavior without creating a different direct birthday-to-testing or birthday-to-infection pathway. Because voting category is ecological rather than individual, interpreting the pattern as individual behavior additionally risks the ecological fallacy.

External validity is weaker because affluent, healthy volunteers need not have the same baseline risk or sugar effect as the UK target population. Generalization requires either negligible effect modification by selection-related characteristics or standardization and inverse-probability weighting to the target population using variables measured in both sources. The unweighted estimate should otherwise be described as an effect for Biobank-like participants.

If sex predicts apprenticeship uptake, extreme UTC sex ratios create both confounding and weak overlap. Matching only the aggregate percentage of boys may leave no genuinely comparable control, and an additive distance can hide a large imbalance in this influential variable. Sex may also be an effect modifier, so the UTC effect can differ across these unusual compositions. One should enforce close sex-ratio balance and estimate sex-specific effects before standardizing them to the intended policy population.

Transitivity requires the studies of different treatment comparisons to be sufficiently comparable in distributions of effect modifiers, outcome definitions and other design features to support an indirect treatment comparison in one target population. For example, a treatment that works differently by disease severity cannot safely be compared indirectly across trials with systematically different severity distributions. Statistical consistency is an implication of suitable transitivity and modeling assumptions, not a substitute for assessing them.